>

Dr Steve Pegg PMP -Lead Consultant & Director of PMd3

After working in the Pharmaceutical industry for most of my career which included over 20 years working in Project Management I gained considerable insight into many Project & Portfolio Magement (PPM) tools and techniques and their effectiveness. I have strong project management skills combined with strong IT skills which gives me a powerfull advantage on technology based projects. I have considerable experience working on PPM Systems including MS Project and Planisware and I have developed bespoke web-based planning tools and data visualisations. I developed several MS Excel applications to facilitate planning & control, team working and stakeholder engagement. Several of these tools were adopted and became standard practice. I have good financial awareness and have developed a fully automated website for an Investment Club for which I am also the treasurer.

 

Lindsay Pegg -Consultant & Director of PMd3

I have 25 years of Pharmaceutical Clinical Development experience across all phases of clinical drug development from pre-nomination, across phase I-III and Life Cycle Management. I have a proven track record of delivery and have successfully led global cross-functional drug projects and improvement initiatives to deliver to time, cost and quality. I have extensive first and second line people management experience including recruitment, training and development, mentoring and coaching.


   

Mike Arnstein -Consultant

Mike, a pharmacology and biochemistry graduate of Liverpool University, has worked in the Pharmaceutical industry for more than 30 years in a number of roles from Discovery Research through Phase I to Phase IV clinical trials. Mike’s principle strengths as a project manager lie in working globally (EU, USA & Japan), “virtually” and getting the most out of people as individuals and in collaborative teams. Mike was the project manager at AstraZeneca for the following successful multi-million dollar products in the cardiovascular, respiratory and CNS therapy areas: Accolate, Corwin, Diprivan, Pulmicort, Rhinocort, Symbicort, Zomig and Zestril as well as candidate drugs in Phase I and II development. He has also worked on MultistemR for Pfizer; in head and neck cancer for a small biotech in Canada and most recently as a Clinical Project Manager/Consultant with Celgene in Switzerland.